{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:45:21Z","timestamp":1792255521706,"version":"4.4.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtho.2026.103711","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T13:10:54Z","timestamp":1775135454000},"page":"103711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Targeting MET in EGFR-Mutated NSCLC"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3520-9464","authenticated-orcid":false,"given":"Stephanie P.L.","family":"Saw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly S.C.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sehhoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Menis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Brand\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizza E.L.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Remon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2026.103711_bib1","author":"Jeon"},{"key":"10.1016\/j.jtho.2026.103711_bib2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41568-018-0002-y","article-title":"Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy","volume":"18","author":"Comoglio","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2026.103711_bib3","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41571-025-01051-9","article-title":"Evolving roles of MET as a therapeutic target in NSCLC and beyond","volume":"22","author":"Lee","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41571-020-0377-z","article-title":"MET-dependent solid tumours - molecular diagnosis and targeted therapy","volume":"17","author":"Guo","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jtho.2022.10.015","article-title":"MET alterations in NSCLC-current perspectives and future challenges","volume":"18","author":"Remon","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_432516","article-title":"New treatment options for patients with oncogene-addicted non-small cell lung cancer focusing on EGFR-mutant tumors","volume":"44","author":"Saw","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jtho.2026.103711_bib7","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/JCO.18.00177","article-title":"Clonal MET amplification as a determinant of tyrosine kinase inhibitor resistance in epidermal growth factor receptor-mutant non-small-cell lung cancer","volume":"37","author":"Lai","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib8","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/annonc\/mdn635","article-title":"MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients","volume":"20","author":"Cappuzzo","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102444","article-title":"Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision","volume":"110","author":"Lai","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtho.2026.103711_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108081","article-title":"Genomic analysis of comprehensive next generation sequencing data to explore the criteria for MET amplification as an actionable biomarker in NSCLC","volume":"199","author":"Tsui","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2026.103711_bib11","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.jtho.2024.09.184","article-title":"FLAURA2: resistance, and impact of baseline TP53 alterations in patients treated with 1L osimertinib \u00b1 platinum-pemetrexed","volume":"19","author":"Yang","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib12","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(24)00270-5","article-title":"Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (Insight 2): a multicentre, open-label, phase 2 trial","volume":"25","author":"Wu","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/2159-8290.CD-22-0586","article-title":"Osimertinib + savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON","volume":"13","author":"Hartmaier","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2026.103711_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100451","article-title":"Unraveling the significance of MET focal amplification in lung cancer: integrative NGS, FISH, and IHC investigation","volume":"37","author":"Xiang","year":"2024","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2026.103711_bib15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(25)01811-2","article-title":"Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial","volume":"407","author":"Lu","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2026.103711_bib16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.lungcan.2017.07.021","article-title":"Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: results from the European Thoracic Oncology Platform (ETOP) Lungscape project","volume":"111","author":"Bubendorf","year":"2017","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.jtho.2026.103711_bib17","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2340\/1651-226X.2025.44344","article-title":"Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer","volume":"64","author":"Bar","year":"2025","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41698-025-01144-9","article-title":"MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer","volume":"9","author":"Tsao","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib19","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2025.04.003","article-title":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and\/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study","volume":"36","author":"de Marinis","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib20","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/s41467-025-67950-8","article-title":"Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS)","volume":"17","author":"Li","year":"2026","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2026.103711_bib21","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab vedotin monotherapy in patients with previously treated c-met protein-overexpressing advanced nonsquamous EGFR-Wildtype non-small cell lung cancer in the Phase II LUMINOSITY trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.annonc.2025.01.001","article-title":"Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced\/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib","volume":"36","author":"Horinouchi","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e22515","article-title":"Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: a case report","volume":"9","author":"Xiang","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.jtho.2026.103711_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.965741","article-title":"Case report: success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation","volume":"12","author":"Takamori","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib25","article-title":"14 skipping mutations in non\u2013small-cell lung cancer: an overview of biology, clinical outcomes, and testing considerations","volume":"5","author":"Socinski","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib26","doi-asserted-by":"crossref","first-page":"S1563","DOI":"10.1016\/j.annonc.2022.10.354","article-title":"LBA12 Tumour genomics in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib in the phase II ELIOS study","volume":"33","author":"Ahn","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib27","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.9074","article-title":"Detection of MET amplification (MET amp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib","volume":"41","author":"Yu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib28","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jtho.2025.10.009","article-title":"Osimertinib plus savolitinib in patients with EGFR-mutated advanced NSCLC with MET alterations after first-line osimertinib: clinical outcomes, safety, and biomarker analysis: a brief report","volume":"21","author":"Le","year":"2026","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13059-024-03294-8","article-title":"Evaluation of somatic copy number variation detection by NGS technologies and bioinformatics tools on a hyper-diploid cancer genome","volume":"25","author":"Masood","year":"2024","journal-title":"Genome Biol"},{"key":"10.1016\/j.jtho.2026.103711_bib30","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.22.00739","article-title":"Phase Ib study of telisotuzumab vedotin in combination with erlotinib in patients with c-met protein-expressing non-small-cell lung cancer","volume":"41","author":"Camidge","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib31","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40265-021-01477-2","article-title":"Targeted therapy approaches for MET abnormalities in non-small cell lung cancer","volume":"81","author":"Garon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jtho.2026.103711_bib32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jtho.2019.11.024","article-title":"Circulating tumor DNA analysis for patients with oncogene-addicted NSCLC with isolated central nervous system progression","volume":"15","author":"Aldea","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib33","article-title":"Targeting MET in NSCLC: an ever-expanding territory","volume":"5","author":"Han","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2026.103711_bib34","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S2213-2600(20)30154-5","article-title":"Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (Insight study): an open-label, phase 1b\/2, multicentre, randomised trial","volume":"8","author":"Wu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2026.103711_bib35","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4143\/crt.2018.052","article-title":"Acquired resistance of MET-amplified non-small cell lung cancer cells to the MET inhibitor capmatinib","volume":"51","author":"Kim","year":"2019","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.jtho.2026.103711_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2022.07.745","article-title":"EP08.02-063 SANOVO: a phase 3 study of savolitinib or placebo in combination with osimertinib in patients with EGFR-mutant and MET overexpressed NSCLC","volume":"17","author":"Zhou","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib37","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2018.77.7326","article-title":"Phase Ib\/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer","volume":"36","author":"Wu","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib38","article-title":"Phase I\/II study of capmatinib plus erlotinib in patients with MET-positive non-small-cell lung cancer","volume":"1","author":"McCoach","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114182","article-title":"Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer","volume":"208","author":"Felip","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2026.103711_bib40","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.8632","article-title":"Vebreltinib plus PLB1004 in EGFR-mutated NSCLC with acquired MET amplification or overexpression after failure on EGFR-TKI treatment: a phase Ib\/II study","volume":"43","author":"Zhou","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cllc.2025.10.018","article-title":"Savolitinib plus osimertinib in epidermal growth factor receptor-mutated, MET-amplified advanced non-small cell lung cancer: a randomized phase II trial","volume":"27","author":"Yang","year":"2026","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2026.103711_bib42","first-page":"387","article-title":"Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: navigating early to advanced disease management","volume":"75","author":"Borgeaud","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtho.2026.103711_bib43","first-page":"S468","article-title":"EP08.02-138 SAFFRON: Ph3 savolitinib + osimertinib vs chemotherapy in EGFRm NSCLC with MET overexpression\/amplification post-osimertinib","volume":"17","author":"Lu","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib44","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jtho.2026.103711_bib45","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jtho.2026.103711_bib46","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1158\/1078-0432.CCR-16-1568","article-title":"ABBV-399, a c-met antibody-drug conjugate that targets both MET-Amplified and c-met-overexpressing tumors, irrespective of MET pathway dependence","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.103711_bib47","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1158\/1535-7163.MCT-21-0009","article-title":"A biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that are unresponsive to MET Pathway Blockade","volume":"20","author":"DaSilva","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2026.103711_bib48","doi-asserted-by":"crossref","first-page":"51311","DOI":"10.18632\/oncotarget.9697","article-title":"The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer","volume":"7","author":"Gou","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2026.103711_bib49","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241279715","article-title":"Landscape of C-MET overexpression in non-small cell lung cancer: a large-scale study of clinicomolecular features and prognosis based on Chinese data","volume":"16","author":"Zhan","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib50","article-title":"Telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein\u2013targeting antibody-drug conjugate (ADC), in patients (pts) with advanced EGFR -mutated (MT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): results from a phase 1 study","volume":"43","author":"Camidge","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib51","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8593","article-title":"A phase 1\/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC","volume":"40","author":"Drilon","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib52","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS3156","article-title":"Egret: a first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors","volume":"41","author":"Aggarwal","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib53","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/1535-7163.MCT-23-0784","article-title":"MYTX-011: a pH-dependent anti\u2013c-MET antibody\u2013drug conjugate designed for enhanced payload delivery to c-MET\u2013Expressing tumor cells","volume":"23","author":"Gera","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2026.103711_bib54","article-title":"Phase 1 study of SHR-1826, a c-MET\u2013directed antibody-drug-conjugate (ADC), in advanced solid tumors","volume":"43","author":"Zhang","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib55","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cllc.2022.11.004","article-title":"Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications","volume":"24","author":"Cho","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2026.103711_bib56","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall survival with Amivantamab-Lazertinib in EGFR-mutated advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103711_bib57","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103711_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.595","article-title":"516MO Efficacy and safety of MCLA-129, an anti-EGFR\/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)","volume":"34","author":"Cappuzzo","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib59","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib60","doi-asserted-by":"crossref","first-page":"S1244","DOI":"10.1016\/j.annonc.2024.08.2296","article-title":"LBA54 Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: second interim overall survival from MARIPOSA-2","volume":"35","author":"Popat","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib61","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.24.01001","article-title":"Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor-mutated non-small cell lung cancer: primary results from the Phase III PALOMA-3 study","volume":"42","author":"Leighl","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib62","doi-asserted-by":"crossref","first-page":"S951","DOI":"10.1016\/j.annonc.2021.08.1797","article-title":"1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: analysis from the CHRYSALIS study","volume":"32","author":"Leighl","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib63","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1038\/s41591-023-02554-7","article-title":"Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial","volume":"29","author":"Cho","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2026.103711_bib64","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jtho.2024.12.029","article-title":"Amivantamab plus lazertinib in patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy: results from CHRYSALIS-2 cohort A","volume":"20","author":"Besse","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib65","article-title":"Efficacy and safety of MCLA-129, an EGFR\/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC)","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib66","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.annonc.2022.02.031","article-title":"22P EMB-01: an EGFR-cMET bispecific antibody, in advanced\/metastatic solid tumors phase I results","volume":"33","author":"Qing","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib67","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00280-018-3623-7","article-title":"A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer","volume":"82","author":"Patnaik","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jtho.2026.103711_bib68","doi-asserted-by":"crossref","first-page":"S1245","DOI":"10.1016\/j.annonc.2024.08.2297","article-title":"LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: an early analysis from the phase III MARIPOSA study","volume":"35","author":"Besse","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib69","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jtho.2025.01.018","article-title":"Preventing infusion-related reactions with intravenous amivantamab-results from SKIPPirr, a Phase 2 study: a brief report","volume":"20","author":"Spira","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2025.09.161","article-title":"MA08.05 PALOMA-2: subcutaneous amivantamab administered every 4 weeks plus lazertinib in first-line EGFR-mutated advanced NSCLC","volume":"20","author":"Scott","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib71","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.jtho.2025.07.117","article-title":"Enhanced versus standard dermatologic management with amivantamab-lazertinib in EGFR-mutated advanced NSCLC: the COCOON global randomized controlled trial","volume":"20","author":"Cho","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib72","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103711_bib73","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.9013","article-title":"Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR -mutated NSCLC in the post-osimertinib setting: analysis of tissue IHC and ctDNA NGS","volume":"41","author":"Besse","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.jtho.2026.103711_bib74","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jtho.2025.09.154","article-title":"MA07.07 validation analysis of MET IHC as a biomarker for Amivantamab-Lazertinib response in post-osimertinib EGFR-mutated NSCLC","volume":"20","author":"Besse","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib75","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from Phase 1 of the blueprint PD-L1 IHC assay comparison project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib76","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","article-title":"PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint Phase 2 project","volume":"13","author":"Tsao","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103083","article-title":"Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: what have we accomplished so far?","volume":"143","author":"Cheo","year":"2026","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtho.2026.103711_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108579","article-title":"Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer","volume":"205","author":"Leighl","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2026.103711_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2025.09.1118","article-title":"PT1.03.06 mechanisms of acquired resistance to first-line amivantamab plus Lazertinib vs Osimertinib: updated analysis from MARIPOSA","volume":"20","author":"Hayashi","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103711_bib80","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf194","article-title":"Mitigation and management of adverse events associated with amivantamab therapy","volume":"30","author":"Florez","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2026.103711_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115631","article-title":"Prospective investigation of biomarker and resistance mechanism using longitudinal cell-free NGS in non-small cell lung cancer with EGFR exon 20 insertion treated with amivantamab","volume":"226","author":"Park","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2026.103711_bib82","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.jtho.2023.09.107","article-title":"OA21.06 ctDNA dynamics, prognostic markers and resistance mechanisms in tepotinib-treated METex14 skipping NSCLC in the VISION trial","volume":"18","author":"Le","year":"2023","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426001644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426001644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:40:42Z","timestamp":1783071642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086426001644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":82,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1556086426001644"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103711","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting MET in EGFR-Mutated NSCLC","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103711","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"103711"}}